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Abstract: Left sided endocarditis (LSE) can include the entirety or portion of mitral and/or aortic valve
and the structures in their anatomical contiguity and represent a significant portion of emergency surgical
activity. Literature and guidelines on the management of LSE relies mainly on observational studies given
the difficulty in designing randomized trials in emergency settings. Heart teams (HT) are often called in to
difficult decisions on the most appropriate strategy to adopted in case of LSE. Decision-making should take
into account the localization and the extension of the infection, patient preoperative status and comorbidities,
presence of a previous valve prosthesis and best timing for surgery. Despite evidence suggests that early
surgery may improve survival in patients with complicated infective endocarditis (IE), an increased risk of
recurrence and postoperative valvular dysfunctions has been reported. The most important factors associated
with long-term outcomes are preoperative multiorgan failure, prosthetic mechanical valve IE, vegetation
size ≥15 mm, and timing of surgical treatment. Importantly, up to one third of potential candidates do not
undergo surgery and these patients experience extremely high mortality rates. Another important point
regards the choice of the optimal valve substitute to be used according to the different clinical situation. The
lack of RCT in this field and the difficulty to design this type of studies in the case of non-elective conditions
further complicates the possibility to achieve a univocal consensus on the best strategy to be adopted in each
form of LSE and further validation studies are needed. On the basis of the current evidences a decisional
algorithm is proposed summarizing all the crucial aspects in the management of LSE.
Keywords: Left side infective endocarditis; mechanical valves; biological substitute; guidelines; treatment and
management
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Introduction
Left sided endocarditis (LSE) is an infection of the entirety
or portion of mitral and/or aortic valve and the structures
in their anatomical contiguity. It may be determined by
various pathogens, but bacterial origin is the most common.
In developed countries, LSE are one of the most common
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causes of acute valves failure. In some reports, the estimated
annual prevalence of infective endocarditis (IE) was 3 to 9
cases per 100,000 persons (1,2) and LSE affects native valves
in 64% to 76.2% of the cases (3-5) and prosthetic valves in
89.9% (PVE) (6,7).
In patients with LSE, age, evolutive cardiogenic shock,
PVE, left ventricular ejection fraction (LVEF) <40%, and
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recurrent infections are considered significant predictors
of mortality (6-9). However, current evidence regarding
the treatment and management strategy for LSE are not
univocal and are often based on empirical practice.
This report aims at reviewing the current evidences on
LSE and provides a basis for the management of this disease
focusing on aspects of the heart team (HT) approach, on
the selection of the most appropriate surgical strategy and
on the importance of physician-patient discussion about the
risks, benefits, and expectations after the surgery.
We present the following article in accordance with the
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/atm-20-4439).
Methods
In December 2019, a search of the PubMed database using
the terms “endocarditis”, “left side endocarditis”, “heart
valve prosthesis”, “allograft”, “autograft”, “cardiac valve
surgery”, “aortic valve replacement” was coordinated.
Qualified abstracts were reviewed and the related articles
were investigated. References for all selected studies were
cross checked. Data from randomized controlled trials
(RCT), unmatched observational series, observational
series corresponding to propensity, meta-analysis, registries
and expert opinion were included. It should be noted that
weight of evidence regarding the different valve substitutes
was not comparable among groups given the significantly
larger number of observations for patients with xenograft
(N=4,111), homografts (N=2,454) in comparison to
mechanical prosthesis (N=655) Ross operation and valve
repairs. Despite the majority of the observational studies
are propensity matched, the lack of RCT and a number
of other confounders limited the power of the analysis
(Tables 1,2).
Management of LSE
The approach
In the 21st century the central role of the multidisciplinary
team emerged in the treatment of endocarditis and this is
crucial for LSE management. Early diagnosis of the either
native valve endocarditis (NVE) and PVE can favor both
the optimization surgical timing and avoidance of potential
complications.
Lack of multidisciplinary integration could lead to delay
in diagnosis, late referral for surgery of patients in more
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critical conditions after failure of medical treatment.
In an Italian study, a formalized multidisciplinary team
approach including (I) initial evaluation within the first
12 hours, (II) indication for early surgery within 48 hours
and (III) a re-evaluation of the patient’s clinical condition
every week, led to a reduction in hospital mortality from
28% to 13% (P=0.02) and in 3-year mortality from 34% vs.
16% (P=0.0007), regardless age and comorbidities (38). The
importance of tertiary centers with advanced surgical and
management competencies is even more evident in complex
LSE, and referral to these units can be advantageous not
only in terms of clinical outcomes but also in terms of costeffectiveness for the national health systems. However,
potential criticisms to this organizational model might
regard the depletion of trained physicians in peripheral
hospitals and the potential delays in transferring patients.
The treatment of IE in the current era requires a
reconfiguration in the organizational standard towards a
centralized system of care or, alternatively, the creation of
a hub-and-speak model that is based on the activity of a
multidisciplinary center reviewing clinical cases. This model
would allow rapid and qualified initial management of IE
and should be established on the basis of clinical evidence.
There is no reason to doubt that the implementation of
a centralized care can improve decision making, surgery
timing, and short- and long-term results. Furthermore, the
efficacy and validity of a centralized model could be readily
tested in a study evaluating the difference between the
before and after its creation (Figure 1).
Risk assessment
The risk assessment models for LSE aimed to assist the
decision-making process of multidisciplinary team has a
pivotal role during the discussion in HT (Figure 1, Table 3).
Gaca et al. (39) elaborated a surgical risk score for the IE
based on the Society of Thoracic Surgeon’s database. The
authors identified 13 risk factors for mortality, including
emergency status, cardiogenic shock, hemodialysis, and
“active endocarditis”.
Another single-center pilot study (40) included 440
patients who had the surgery for NVE and reported six
predictors for early postoperative mortality. Variables were
entered in a mathematical model with good predictivity
[area under receiver operating characteristic curve (AUCROC) of 0.88]. The authors identified six predictors along
with their assigned scores including age (5–13 points),
renal failure (5), NYHA class IV (9), critical preoperative
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Table 1 Observational studies and propensity matched comparing the allogenic and autologous substitute with conventional prosthesis
Number of
Total
First author (Ref.)
patients/
sample (N)
endocarditis

Number of aortic
Mean
valve substitute
follow-up/
Main findings
implanted or
months
repair

Nappi 2018,
JTCVS (10)

210

118

162

Ao-H [210]; χ
Ao/Mitr-H [11]

Schaefer 2018,
PLoS One (11)

#

35

48.7

SFS [77] (IE 19); 30-day mortality (SFS 3/77; 3.9% vs. CP 4/77; 5.2%; P=0.699).
XP [77] (IE 16)
All-cause mortality (SFS 20.8% vs. CP 14.3%; P=0.397); SVD
(5.2% SFS vs. 0% CP; P=0.04); Reoperation due to SVD or
prosthetic valve endocarditis (PVE) (9.1% SFS vs. 1.3% CP;
P=0.04). Inferior survival after NVE in re-do surgery in SFS
group (HR: 7.63; CI: 1.65±35.25, P=0.009)

190

144

Ross Operation

30 days mortality for the total study population of 2.1%.
Survival 93.8% [95% confidence interval (CI): 90.2–97.7) at
10 years and 86.1% (95% CI: 78.8–94.0) at 20 years. Freedom
from reoperation on the auto- and homograft 94.1% (95% CI:
83.6–100.0) at 5 years, 87.4% (95% CI: 72.4–100.0) at
10 years, and 71.5% (51.1–100.0) at 15 years. Lower incidence
of reoperation for autograft endocarditis 0.4%

154

Ratschiller 2017, 190
Semin Thorac
Cardiovasc
Surg (12)

Similar survival at 15 years Ao-H (61.3%) vs. stented xenograft
(62.1%) and vs. mechanical prosthesis (60.6%); 15 years
freedom from reoperation SVD 89.4%. Freedom from IE 98.1%
at 20 years. MACCEs freedom from event at 15 years 50.6%

Kim 2016,
JTCVS (13)

304#

304

29.4

Ao-H [86]; MP
[79]; XP [139]

Similar survival between valve substitute. Odds ratio 1.61; 95%
confidence interval (CI), 0.73–3.40, P=0.23 (HR 1.10; 95% CI,
0.62–1.94, P=0.75). Reinfection 7.7%. No difference in freedom
from reinfection rates (P=0.65). CAH did not significantly affect
reinfection (HR 1.04; 95% CI, 0.49–2.18, P=0.93)

Kim 2016,
JTCVS (14)

436#

IVDU 78;
Non-IVDU
358

29.4

Ao-H [86]; MP
[99]; XP [206]

Similar survival between group (IVDU vs. Non IDVU). (HR, 0.78;
95% CI, 0.44–1.37). No difference between valve substitute.
Lower operative mortality in IVDUs (odds ratio, 0.25; 95%
CI, 0.06–0.71). Better valve-related complications in IVDUs
(HR, 3.82; 95% CI, 1.95–7.49; P<0.001) for higher rates of
reinfection (HR, 6.20; 95% CI, 2.56–15.00; P<0.001)

Perrotta 2016,
Ann Thorac
Surg (15)

84

84

65

Ao-H [56]; MP
[20]; XP [12]

10 years similar survival. CAH 58% vs. conventional prosthesis
75% (P=0.17). Higher incidence of reoperation for infection
relapse in mechanical or xenograft valve prosthesis (12.9%)
than CHA (0%) (P=0.006). Lower incidence of reoperation for
SVD in CAH at 10 years (5.3%)

Arabkhani 2016,
JTCVS (16)

353

115

137

Ao-H [115]

20 years survival 40.0% at (95% CI, 32–50%). 20 years
predicted competing-risks analysis 31% death without
reoperation, 39% reoperation, and 30% alive without
reoperation. Low incidence of infection relapse (3.96%) and
reoperation (2.26%)

Flameng 2015,
Ann Thorac
Surg (17)

69

69

96

Ao-H [69]

10 years survival 73%. 10 years freedom of reoperation 74%.
Lower incidence of infection relapse and reoperation for IE
(4.34%). Higher incidence of reoperation for SVD (18.84%)

111

79

XP [111] (CP
bioprosthesis)

15- and 20-year survival 31.1% and 14.4% (95% CI). IE early

Bourguignon
2,559
2015, Ann
Thorac Surg (18)
Table 1 (continued)
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Table 1 (continued)
Number of
Total
First author (Ref.)
patients/
sample (N)
endocarditis

Number of aortic
Mean
valve substitute
follow-up/
Main findings
implanted or
months
repair

Johnston 2015,
Ann Thorac
Surg (19)

12,569

450

68

XP [450] (CP
bioprosthesis)

76% probability of death before explant for SVD and
endocarditis at 20 years. Few probabilities of explantation for
SVD (5.4%) and endocarditis (1.4%) at 20 years

Chiang 2014,
JAMA (20)

#

2,002

16

128

MP [9]; XP [7]

No difference in 30-day mortality XP (3%) vs. MP (3%) (P=0.49);
No difference survival (P=0.74); 15-year survival XP (60.6%;
95% CI, 56.3–64.9%) vs. MP (62.1%; 95% CI, 58.2–66.0%).
HR 0.97 (95% CI, 0.83–1.14). 15 years reoperation XP (12.1%)
vs. MP (6.9%) (95% CI, 8.8–15.4% vs. 95% CI, 4.2–9.6%. HR:
0.52; 95% CI, 0.36–0.75)

Hussain 2014,
JTCVS (21)

#

775

537

84

Ao-H [357]; MP
[25]; XP [139]

30 days mortality 7% for aortic valve and 14% for aortic and
mitral valve IE. Survival at 5 years 75%. Rate of recurrence of
infection 5.1%

101

420

Ao-H [101]

35 years survival 66%. 35 years reoperation rate for SVD
33.9%. 2 pts with CAH for more than 30 years. Lower
incidence of infection relapse and reoperation for IE. Early
reinfection 0.2%. Late relapse of IE 5.5%

44

XP [617]
5 years survival 69.6% (95% CI, 65.7–73.9). Early SVD. 1-, 2-,
Mitroflow
and 5-year 0.2% (95% CI, 0.0–0.6), 0.8% (95% CI, 0.0–1.6),
(models 12A/LX) and 8.4% (95% CI, 5.3–11.3). 5-year SVD-free survival 91.6%
(95% CI, 88.7–94.7). 13 patients accelerated SVD

Fukushima 2014, 840
JTCVS (22)

Sénage 2014,
Circulation (23)

617

Glaser 2014, Ann 1,219
Thorac Surg (24)

8

50

XP (CP 864); XP No difference 8 years survival CP (63%) vs. Mosaic (57%)
(Mosaic 365)
(P=0.971). (HR, 0.85; 95% CI, 0.65–1.11). No difference in
reoperation (P=0.745). Lower incidence of IE recurrence

Grubitzsch 2014, 149
JTCVS (6)

96

48

MP [11]; XP [80]; Early death 31.5%. Late death 7.38%; overall and event-free
Ross
survivals at 10 years were 75% +/- 3.8% and 64%, 4.0%;
Procedure [5]
Freedom from recurrent infection and reoperation at 10 years
were 81% +/- 3.6% and 91% +/- 2.6%

Kowert 2012, Eur 363
J Cardiothorac
Surg (25)

363

100

Ao-H [363]

Early death 8.9%. Survival 1 year (86%) and 5 years (77.4%).
Mean time between homograft implantation and redo operation
8.4±3.6 years. Early and late recurrent endocarditis 9%
(prior IE)

Manne 2012,
Ann Thorac
Surg (5)

428

282

12

Ao-H [173]; MP
[24]; XP [84];
Ross operation
[1]; Ao-R [12]

Higher 30-day mortality PVE vs. NVE (13% vs. 5.6%;
P<0.01). No difference in survival NVE vs. PVE (35% vs.
29%; P=0.19). Higher 30 days mortality and 1 year mortality
for Staphylococcus aureus infection (15% vs. 8.4%; P<0.05)
and (28% vs. 18%; P=0.02). Few reoperation for persistent
infection or relapse (2.4%)

Mayer 2012, Eur
J Cardiothorac
Surg (26)

100

100

31

MP [10]; XP [51]; Similar 30-day mortality Ao-R 9% vs. Ao-Rpl 18% (P=0.37).
Ross operation Better survival Ao-R (88%) vs. Ao-Rpl (65%) (P=0.047). Higher
[6]; Ao-R [33]
rate of reoperation Ao-R (35%) vs. Ao-Rpl (10%) (P=0.021)

Bekkers
2011, Eur J
Cardiothorac
Surg (27)

262

96

102

Ao-H [96]

30-day mortality 5.7%. Survival 77.0% (95% CI, 71–83%) at
10 years, and 65.1% (95% CI, 57–74%) at 14 years. Survival after
re-operation 87.1% at 1 year and 79.3% at 9 years. Freedom
from allograft re-operation 82.9% at 10 years and 55.7%
(SE 5.7%) at 14 years. SVD 18.5% and infection relapse 0.7%

Table 1 (continued)

© Annals of Translational Medicine. All rights reserved.

Ann Transl Med 2020;8(23):1627 | http://dx.doi.org/10.21037/atm-20-4439

Annals of Translational Medicine, Vol 8, No 23 December 2020

Page 5 of 19

Table 1 (continued)
Number of
Total
First author (Ref.)
patients/
sample (N)
endocarditis

Number of aortic
Mean
valve substitute
follow-up/
Main findings
implanted or
months
repair

Musci 2010,
JTCVS (28)

1,136

1,136

62

Ao-H [221]

10 years survival 47.3%±5.6%. Lower incidence (5.4%) of
infection relapse and reoperation for IE. Lower incidence of
reoperation for SVD 8.6%

El-Hamamsy
2010, JACC (29)

166

4

90

Ao-H [76];
Freestyle
bioprosthesis
[90]

Freestyle less progressive aortic valve dysfunction and a lower
need for reoperation (100%±0% vs. 90%±5%; P=0.02). 30-day
mortality 4.8%. No difference in survival freestyle vs. homograft
(80 +/-5% vs. 77 +/- 6%; P=0.9)

Nguyen
2010, Eur J
Cardiothorac
Surg (30)

167

167

60

Ao-H [77]; MP
[109]; XP [31]

30-day mortality XP (19.4%), Ao-H (7.4%), MP (10.1%)
(P=0.27). XP lower overall 5-year survival </=65 years [adjusted
HR 4.14 (1.27–13.45), P=0.018] but not >65 years [adjusted
HR: 1.45 (0.35–5.97), P=0.60]. No difference between Ao-H
and MP [HR 0.46; 95% CI, (0.15–1.42), P=0.18]

Klieverik 2009,
Ann Thorac
Surg (31)

138

138

96

Ao-H [106]; MP
[32]

Higher 30-day mortality for CAH (P=0.25). No difference in
survival at 15 years (CAH 59%±6% and MP 66%±9% (P=0.68)
and freedom from recurrent infection (P=0.29). Higher rates of
reoperation for CAH (P=0.02)

David 2007,
JTCVS (3)

383

383

73

Ao-H [18]; MP
[214]; XP [133]

15 years survival 44%. Relapse of IE independent predictors
of death (HR 2.2, 95% CI, 1.2–3.9). 15 years freedom from
recurrent IE 86% for all patients without difference between
type of valve implanted. 15 years freedom from reoperation
70%

Yankah 2002,
EJCTS (14)

816

816

60

Ao-H [182]

10 years survival 91%. Lower incidence of early (2.7%) and
late (3.6%) infection relapse and reoperation for IE (P=0.0001).
10–13 years freedom from reoperation for SVD 85%

Sabik 2002, Ann
Thorac Surg (32)

103

103

51

Ao-H [103]

30-day mortality 3.9%. Survival at 10 years 56%. Few recurrent
PVE at >/=2 years (peaked at 9 months)

306

183

Ao-H [20]; MP
[65]; XP [221]

20 years survival 46% mechanical, 41%, stented xenograft,
58% CAH; P>0.27. Lower risk of infection relapse without
group difference. 5 years 2.1% mechanical prosthesis, 2.3%
stented xenograft, and 3.6% CAH; P>0.88. After 5 years 0.5%
mechanical prosthesis, 1.1% stented xenograft and 3.1%
CAH; P>0.25. 10- and 15-year freedom from reoperation for
mechanical prosthesis 74.6%; 10- and 15-year freedom from
reoperation for xenograft prosthesis 56.6%, 22.6% P>0.64

Moon 2001, Ann 306#
Thorac Surg (31)

Of total N=436 Valve repair was performed in N=45. #, propensity score; χ Ao/Mitr-H, cryopreserved mitro-aortic homograft replacement;
IVDU, intravenous drug user.

status (39), failure to achieve preoperative blood culture
negativity (5) and perivalvular involvement (5). They have
outlined four risk classes ranging from “very low risk” (≤5
points, expected average mortality of 1%), and “very high
risk” (≥20 points, mortality of 43%).
Martínez-Sellés et al. (41) included 26 observational
reports with over 1,000 patients treated for LSE (NVE
=315 and PVE =122). They reported a significant reduction

© Annals of Translational Medicine. All rights reserved.

in in-hospital mortality in patients who underwent early
surgery compared to those were managed with medical
therapy (24.3% vs. 34%; P=0.02). A risk score called
PALSUS was developed which aimed to evaluate hospital
mortality using seven prognostic variables with a similar
predictive value. Variables included were: prosthetic valve,
age ≥70, significant intracardiac destruction, Staphylococcus
spp, urgent surgery, sex [female], EuroSCORE ≥10 (42).
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Table 2 Meta-analysis and registries reporting the use of aortic homograft and conventional
Total
sample (N)

Number of
patients/
endocarditis

Wang 2017, Ann
Thorac Surg (33)

42,305

–

Mean times to valve
failure (MTTF)

Medtronic Porcine
[9,619]; Edwards
Porcine [3,886]; Sorin
Pericardial [6,632];
Edwards Pericardial
[22,177]

Sorin pericardial showed higher
SVD risk; P<0.001 for all other
three valve type (lower riskadjusted MTTF). No significant
differences in SVD risk among
the other three valve types
(P=0.716)

Foroutan 2016,
BMJ (34)

53,884

–

Cumulative incidence
of Death and SVD at
10, 15 and 20 years

Xenograft [53,884]

Survival 89.7%,78.4%, 57.0%,
39.7% and 24.7% at 2, 5, 10,
15 and 20. 10, 15, and 20 years
freedom from SVD 94.0%,
81.7%, 52% at (evaluated for
7,603 pts). SVD increases rapidly
after 10 years, and particularly
after 15 years

Savage 2014, Ann
Thorac Surg STS
database (35)

11,560; 8,491
prior, 3,139
reoperative

11,560

2005 to 2011

Ao-H [588]; XP
[5,396]; MP [2,144];
Other [293]

AVR prior 88.5% vs. reoperative
58.7%; RR prior 7.2% vs.
reoperative 29.9%; Prior
operation XP increased (57%
to 67%). MP decreased (30%
vs. 24%) Ao-H decreased (9%
vs. 6%) P<0.001. Reoperation
XP increased (38% to 52%)
MP decreased (20% vs. 17%)
Ao-H decreased (38% vs. 28%)
P<0.001. Ao-H most used in
reoperation

†

Reece 2014, Ann
Thorac Surg STS
database (36)

2,188

307#

1994 to 2010

Ross [1,094]; NonRoss [1,094]

Ross higher perioperative
complications and operative
mortality (2.7% vs. 0.9%;
P<0.001). Ross vs. No Ross
OR 3.00 (95% CI, 1.47 to 6.11;
P=0.002)

†

39,190

452

150

XP [644]; MP [376]

No difference in survival (HR,
1.04; 95% CI, 1.01–1.07).
XP higher reoperation (HR,
2.55; 95% CI, 2.14–3.03) and
endocarditis (HR, 1.60; 95%
CI, 1.31–1.94), and lower risks
for stroke (HR, 0.87; 95% CI,
0.82–0.93) and bleeding (HR,
0.66; 95% CI, 0.62–0.70)

First author (Ref.)

Brennan 2013,
Circulation (37)

†

Mean follow-up/
months

Number of aortic
valve substitute
implanted

Main findings

, PM; #, all Ross operation.

© Annals of Translational Medicine. All rights reserved.
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Figure 1 Clinical evaluation and diagnosis flowchart for LSE. For detailed explanation and references see text. ACC/AHA, American
College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE, infective endocarditis; LSE, left side
endocarditis; TTE, transthoracic echocardiography.

Hospital mortality ranged from 0% in patients with
a PALSUSE score from 0 to 45.4% in patients with a
PALSUSE score >3. Since the prognosis for IE surgery is
highly variable, the PALSUSE score could help identify
patients with higher hospital mortality.
Timing of surgery
The timing of surgery, especially in emergency status, is a
lively topic of discussion in the HT and is often opposed
to the use of medical treatment. The Heart Team works on

© Annals of Translational Medicine. All rights reserved.

the path laid out by the European Society of Cardiology (43)
and AHA (44) who have classified the appropriate timing
for surgery based on class and level of evidence (Figure 2,
Table 3). The guidelines often do not correlate with real
world scenarios faced by the multidisciplinary team. Chu
et al. (45) highlighted that the main predictive factors
for non-surgical referral were liver diseases [odds ratio
(OR) for surgery: 0.16; 95% CI: 0.04 to 0.64], S aureus
infection (OR: 0.50; 95% CI: 0.30 to 0.85) and stroke prior
to surgical decision (OR: 0.54; 95% CI: 0.32 to 0.90). In
contrast, patients with severe aortic regurgitation, abscess

Ann Transl Med 2020;8(23):1627 | http://dx.doi.org/10.21037/atm-20-4439

Nappi et al. Decision-making in LSE

Page 8 of 19
Table 3 Timing for surgery based on guidelines based evidence and clinical situation
Clinical situation

Surgical timing

Level of evidence

Large vegetation (>15 mm), heart failure, periannular abscess

Immediate intervention required

Class Ia, level B

Minor cerebral event (transient ischemic attach of silent
cerebral embolism)

Immediate intervention required

Class I, level B

Stroke without evidence of cerebral hemorrhage or coma

Immediate intervention possible

Class IIa, level B

Stroke with suspicion of intracranial hemorrhage or cerebral
septic emboli with potential hemorrhagic evolution

Defer surgery for 1 month; Obtain CT scan Class I, level C

39

40
41
43
45

46
4
47
48
49
50
8

Figure 2 Studies reporting the risk assessment in patients with LSE (4,8,39-42,45-50). NVE, native valve endocarditis; OMT, optimal
medical therapy; ACC/AHA, American College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE,
infective endocarditis; LSE, left side endocarditis; TTE, transthoracic echocardiography.

and embolization were likely to undergo surgery. The
authors concluded that surgical decision making in LSE
is largely consistent with established guidelines, however
nearly a quarter of patients with surgical indications did
not receive surgery. Furthermore, evidence shows that the
presence of the pathogen S. aureus in LSE was significantly
associated with non-surgical management (45). The STS-IE
score provides prognostic information for survival after the
operative period, but a significant proportion of operations
are actually never performed.
In LSE the timing of surgical treatment is closely related
to the appearance of the neurological complication. In
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patients with stroke, surgery should not be postponed in the
absence of coma and cerebral hemorrhage (class IIa, level
B). The diagnosis of minor neurological events, such as the
appearance of a transient ischemic attack or silent cerebral
embolism, are criteria to recommend surgery without delay
(class 1, level B) (43).
In contrast, the manifestation of devastating neurological
events, such as intracranial hemorrhage and brain
localization of septic emboli with an CT features indicating
hemorrhagic evolution, should delay surgery by at least
1 month. According to the guidelines, repeated CT scans
or MRI perfusion scans allow to evaluate the progression of
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the lesion (class IIa, level B) (43).
Okita et al. (46) retrospectively reported a multicenter
cohort of 568 patients undergoing surgery for active LSE.
Of those 118 patients had non-haemorrhagic cerebral
infarction, 54 had intracranial hemorrhage and 396 had
no brain events. Patients with non-haemorrhagic injury
in which surgery was postponed for 2 weeks after the
neurologic event had a higher incidence of hospital death.
In particular, patients who were operated between 15 and 28
days or after 29 days from the onset of non-haemorrhagic
cerebral infarction had higher incidences of hospital death
compared with those who had surgery within 7 days. [Odds
ratio 5.90 (P=0.107) and 4.92 (P=0.137)]. Conversely,
in presence of intracranial hemorrhage, patients who
received surgery between 8 and 21 days or after 22 days had
lower incidences of hospital mortality compared to early
surgery (within 7 days) [odds ratio 0.79 (P=0.843) and 0.12
(P=0.200)].
Another decisive point of discussion is related to the
priority between early surgery and antibiotics in the
treatment of LSD complicated by heart failure, risk of
embolization or in case of extensive infection. In the past
9 years, several large studies have supported the survival
benefit associated with the use of early surgery in patients
with LSE in larger studies with long-term follow-up.
Gálvez-Acebal et al. (4) in a propensity matched study
on 417 patients with LSE with a mean follow-up was
1.3±21 years showed that early surgery within 48 hours of
diagnosis had a significantly better in-hospital mortality and
late mortality rate than those managed conservatively with
antibiotics [26.8% vs. 41.8%; absolute risk reduction (ARR),
−15.2%; P=0.004 and 29.7% vs. 46.2%; ARR, −16.5%;
P=0.002, respectively]. This study clearly supported the
benefit of surgical treatment of left-sided IE especially
in patients in which moderate or severe heart failure and
paravalvular extension of infection occurred (4).
In another propensity match study from Duke
university (47), on 426 patients with LSE the mortality
rate associated with early surgical management was
decreased (HR, 0.27; 95% CI, 0.13–0.55). Patients who
had an early surgical treatment were more likely to have
Staphylococcus aureus infections, congestive heart failure,
larger vegetations, intracardiac abscess, and undergoing
hemodialysis without a chronic intravascular access.
Diabetes mellitus (HR, 4.81; 95% CI, 2.41–9.62), the
presence of chronic intravenous catheters (HR, 2.65; 95%
CI, 1.31–5.33), and paravalvular complications (HR, 2.16;
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95% CI, 1.06–4.44) were risk factors for mortality
Mirabel et al. (48) included 198 patients who were
prospectively evaluated for IE across 33 adult intensive
care units (ICU) in France, and reported a 69% longterm mortality at median follow-up time of 59.5 months in
critical LSE. Sepsis-related Organ-Failure Assessment score
(SOFA) calculated the day of surgery was the only factor
independently associated with long-term mortality (HR
=1.59; 95% CI, 0.77–3.28 for SOFA 5–9; 3.56, 1.71–7.38
for SOFA 10–14 and 11.58, 4.02–33.35 for SOFA 15–20;
reference category SOFA 0–4; P<0.003).
Samura et al. (49) evaluated the impact of emergency
surgery in 152 patients (45 propensity score-matched pairs)
with left-sided native valve IE complicated with acute
cerebral infarction. The authors reported a significant
higher hospital mortality in patients who underwent
delayed surgery compared to those who received early
valve operation (16% vs. 2%; P=0.058). The survival rates
at 5 years in patients who were managed with early valve
operation was higher than in delayed surgery [97% vs. 80%,
(P=0.029)].
Wang et al. (50) compared the effect of early surgery in
patients with prosthetic valve IE in relation to age, causative
microorganism, intracardiac abscess, and congestive heart
failure. Surgery group (n=145) was associated with higher
survival rates than the antimicrobial therapy group (n=207)
(OR for death, 0.56; 95% CI, 0.23–1.36). Predictive factors
of in-hospital mortality were brain embolization (OR 11.12;
95% CI, 4.16–29.73) and Staphylococcus aureus infection
(OR 3.67; 95% CI, 1.29–9.74).
In a study from Cleveland Clinic (5), surgery for PVE
(n=180) was compared to NVE (n=248) in 428 consecutive
patients who were followed for a maximum of 5 years. Inhospital mortality was higher in PVE vs. NVE group (13%
vs. 5.6%) and, after multivariate analysis, Staphylococcus
aureus infection was the only independent predictors of inhospital death (15% vs. 8.4%; P<0.05), 6-month (23% vs.
15%; P=0.05) and 1-year mortality (28% vs. 18%; P=0.02).
There was a non-significant survival benefit in the PVE
group in respect to NVE (35% vs. 29%; P=0.19).
In large propensity matched study from the International
Collaboration on Endocarditis–Prospective Cohort Study
Investigators (8), including 1,025 PVE patients (aortic
valve, 71%; mitral valve, 45.1%), there was no significant
difference in 30-day and 1 year survival in the early valve
replacement group compared with medical therapy (HR for
death, 0.44; 95% CI, 0.38–0.52, P<0.001 and 0.57; 95% CI,
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0.49–0.67, P<0.001).
Surgery for LSE
Current trends in the surgical practice
The surgery of endocarditis has been regarded as the most
effective strategy for several categories of patients affected
by the LSE. Long-term substitute durability is the key
factor for the success of the surgery in patients with LSE
(10,21,22,28,35,51-53). To date, no definitive guidelines
support the selection of one substitute over the other, and
the choice of the best valve remained more a matter of art
than of science. In the last 4 decades several substitutes have
been proposed, 5 have passed the test of time with different
success: homograft, autograft, stented or non-stented
xenograft prosthesis and mechanical prosthesis.
Currently, the clinical benefits of using conventional
biological prosthesis to replace an infected heart valve are
well established, and this surgical option represents the
tenet of modern valve surgery. Despite robust evidence
suggests that the use of a biological valve, rather than
mechanical prosthesis, is associated with further advantage
in long-term outcomes, the effectiveness and safety of
each substitute is related to the age and location of the
implant (18,19,24,33,34). For mitral valve mechanical valve
represent still an adequate choice in patients up to 70 years
old (54), while the benefit of aortic mechanical prosthesis
disappears after 55 years of age (38,39). The benefit in
terms of lower risk of reoperation with mechanical valves is
counterbalanced by the higher risk of bleeding and stroke in
some age groups (20,54).
Evidence suggests that the choice of a homograft or an
autograft is useful in younger high-risk patients, such as
those with complex valve endocarditis or in patients with
PVE. The benefit of their use becomes more evident within
the first post-operative decade because of the reduced risk
of recurrent infection (10,15-17,22,32,52,53). However,
the risk of structural valve deterioration increases with
time (10,16,22,25,27). The use of cryopreserved homograft
does not change the extent of the survival advantage (13).
Nevertheless, the surgical community seemed reluctant to a
wider adoption to these substitutes for a number of reasons.
A recent analysis of the Society of Thoracic Surgeons
(STS) database revealed that, in the United States, the
use of stented xenograft prosthetic valves is increased and
a total of 8,421 patients (73%) with IE cases received a
conventional biological valves, both for primary operations
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and reoperations, compared to 3,139 patients (27%) who
were managed with mechanical valves (35). The use of
homograft is rare during the primary operation but is
more common in patients requiring reoperation (32.2%
vs. 7.0%, P<0.0001) and when extensive intervention on
the aortic root is required (53.2%) (35). An analysis of the
trend of the last 2 decades, based on a significant amount
of observational data, has showed that the use of homograft
has decreased over time in cases of first-time replacement of
the aortic valve (from 9.4% to 5.6%) and for reoperations
(from 37.5% to 28.5%) (35).
The reasons for the low use of mechanical valves and
homografts are complex and multifactorial. More than two
decades ago data reported by Washington University of
St Louis showed that 50% of patients with IE underwent
surgery with mechanical prosthesis while since 2009 only
14% of the patients were treated with this type of valve. The
evident change in the surgeons’ attitude has been probably
determined on the one hand by the reported trends towards
better survival and complication rate with biological valves,
and on the other, by the increase in re-hospitalization for
clinical events related to anticoagulation-related problems
in recipients of mechanical valves (20,54). In this scenario,
managing both the short term and the long-term adverse
event, including the prevention of thrombotic complication,
can be the drivers of the surgical decision-making process
because of the potential economical implications for the
institutions. In fact, the costs of managing valve thrombosis
was estimated to exceed $30,000 for a single event. The
costs of acute management of embolism and anticoagulantrelated hemorrhage were between $8,000 and $11,500 (55).
The use of homograft and allograft for LSE—when and
how
The reluctance shown by surgeons for the widespread
adoption of cryopreserved homograft in IE finds its roots
in lack of RCT investigating the effective benefit of the
use of these substitutes (10,13,16,22,31,32,51,56,57).
Evidence from several reports have reported no significant
differences in overall mortality and infection recurrence
when comparing mechanical versus biological substitutes
(13,31,51,56,57). Klieverik et al. (56) revealed a similar
rate of recurrent endocarditis in patients who underwent
homografts or mechanical prosthesis implantation, but a
lower freedom from reoperation (76% vs. 93% respectively).
Sabik et al. (32) showed that patients with prosthetic IE,
including 78% with periannular and radical abscesses, had
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a freedom from recurrent infection of more than 2 years
of 95% and an operating mortality of 3.9% when treated
with a homograft. Although the risk of homograft root
re-operation for structural valve deterioration is higher,
reduced rate of reinfection was noted in the long-term
follow-up (between 14 and 27 years) (10,16,17,22,25,27,53),
probably due to their favorable responses to
antibiotics (16,22).
Despite the survival benefits associated with the use of
pulmonary autograft (PA) are well established (29,57-62),
its use to replace the aortic valve is recommended only in
the US guidelines (Class II b, Evidence Level C) (63) and
not mentioned in the European guidelines (43). The use of
autograft in the setting of the LSE has been considerably
reduced because of the indisputable technical complexity
in the execution of the Ross operation. The data from STS
database have showed 3-fold increase in operative mortality
with Ross operation compared with conventional AVR,
probably as an effect of lack of experience of low volume of
cases (36,64). Despite these evident criticalities, the use of
PA in patients with LSE is indicated at a young age or with
contraindication for long-term anticoagulant treatment,
in women of childbearing age, in PVE and in patients who
choose this substitute for the type of style of life they lead
(12,65-68). However, it should be taken into consideration
that potential complications of this operation involve both
the aortic and pulmonary valve and carry an additional
clinical burden (69).
Surgery in complex LSE
Kim et al. (13) reported outcomes of 131 patients treated
with extensive and radical surgery for LSE. Homografts
but also mechanical valves or xenografts have been used in
these cases. The authors found that abscess formation had
an incidence of 43.09%, which is higher than the mean
frequency (36–38%) for LSE of native valve (10,21) and PV
(58%) reported by several international studies (3). Abscess
formation was treated in 40.5% with a mechanical valve and
in 29.5% with xenograft.
The selection of the type of graft to be used should be
guided by several parameters including age, extension of
the infection (especially to the mitral valve), involvement
of other heart structures and resistance to infections. The
latter is particularly important since redo surgery in case
of reinfection is particularly demanding and burdened by
increased perioperative risk and poor early and mid-term
outcomes. It is noteworthy that reinfection of synthetic
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prostheses or prosthetic materials after complex endocarditis
were reported as more daunting and technically demanding
than reinfection occurring on a previous homograft
(10,52,53,62,66-69) (Figure 3).
In this context, evidences on safety and durability of
homograft has been widely reported. A pivotal study of
Stanford University (31) revealed a reinfection rate of
2% at 10 years with the majority of the cases occurring
following aortic valve endocarditis surgery within the
first year. More recently, the group from Cleveland
clinic confirmed the long-term durability and safety of
homografts for LSE with the additional benefit of improved
postoperative hemodynamics and ventricular remodeling.
The fact that no difference in outcomes was demonstrated
between mechanical and biological prostheses suggests
that in complex endocarditis and in patients with extensive
PVE, the choice of the use of an allogeneic tissue is a
priority (5,21).
There is currently a sizable body of evidence to support
the use of homografts in the setting of complex LSE. A
report (17) showed a low recurrence of endocarditis in
homograft even in complex cases. The larger series by
Erasmus group (16) showed very solid results in terms
of mortality and durability. The authors published their
follow-up at 27 years underlying the importance of
homografts in complex endocarditis. Musci et al. (28) used a
homograft aortic roots in active IE with periannular abscess
formation in a large series of patients with LSE showing
satisfactory early and long-term results. Finally, as reported
by Perrotta (15) survival benefit with the use of a homograft
is higher than in prosthetic valves (5-year cumulative
survival 88% versus 66% in prostheses).
Although structural valve deterioration is considered
the Achilles’ heel responsible for the limited use of
allogenic tissue (10,25,27,68,69), relapse of infection
represents a daunting problem in patients treated for
complex active LSE and should be given consideration.
Notably, the reoperation for a relapsing infection carries a
higher mortality than the reoperation for structural valve
deterioration or dysfunction of an aortic homograft inserted
in aortic root position (4–10%) (10,69,70).
Another important point is the reinfection in presence
of the synthetic material. The strong inflammatory reaction
elicited by the foreign material constituting the stent
of mechanical or biological prosthetic valves demands
for extensive demolition and debridement increasing
the complexity of the procedure. However, reoperation
after previous homograft is considered less demanding
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Figure 3 Aortic abscess (A,C) treated using a prosthetic valved conduit with mechanical valve (B,D).

even in the presence of massive calcification of the aortic
root (71-73).
In LSE abscess formation is common. Avoiding the use
of a homograft in favor of a prosthetic valve in aortic IE
implies to treat the abscess with a circumferential patch to
repair the ventricular-aortic discontinuity. Similarly, in the
case of localized lesions involving only a part of the aortic
annulus, the aorto-mitral continuity or aortic root, the
cardiac structure still needs to be reconstituted with use of a
partial Dacron or equine pericardial patch (3,5,21,26,30,32).
Recurrence of LSE involving the myocardium underlying
the left coronary cusp is at even higher-risk and may require
a Bentall or Cabrol operation.
Infection of more than one valve has been reported
in 24.2% to 46.8% of the cases (3,10,13,52) with mitral
or tricuspid valve being more commonly involved in
intravenous drugs user (11).
Clearly, complex LSE treated with prosthetic valves
could lead to a further increase in the risk of mortality in
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the event of extensive reinfection of two prostheses (3,26).
In a very recent Harvard series, associated mitral valve
involvement reached up 25% of the cases (13). We have
proposed the use of a double homograft in complex LSE
with extension to aorto-mitral junction and mitral including
both total and partial mitral insertion techniques with
satisfactory results at 18 years (10,52,53,69).
Surgery and ethical implication
As recommended by current guidelines, selection of the
most appropriate valve replacement strategy in LSE
should consider the longevity of the biological substitutes,
the potential recurrence of infection and the risk of redo
surgery. The best choices are made through a shared
decision-making process that includes the patient, the
patient’s family, an interventional cardiologist, a cardiac
surgeon and, preferably, the patient’s general cardiologist or
general practitioner (43,63).
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Patient’s preferences and will also take a considerable
part in the decision-making. Patients may be discouraged
from large and demanding operation. Therefore, the role
of the heart team is fundamental in providing detailed
explanations of the indications, the steps of the procedure,
the potential complications and the postoperative course
to allow an informed decision-making. In educating the
patient, the experts should explain the potential need for
extensive debridement to obtain good and stable results. For
example, proposing a faster operation by recommending a
prosthetic valve instead of the use of autologous or allogenic
tissue in the context of significant involvement of the aortic
or mitral valves, can provide misleading information about
a situation with a high potential for recurrence of infection.
The decision on the surgical option and the choice of the
ideal substitute always derives from a balance between the
risk of the operation that the surgeon should perform and
the obtainable benefit. In the case of complex LSE, both
the risk of the procedure and the potentially even higher
risk of a redo operation for infection relapse or valve
degeneration should be taken into account. Obviously, these
considerations are also ultimately subjected to the surgeon
and unit’s experience in complex procedures and the option
of referral to tertiary centers should be explored according
to the clinical conditions.
Interestingly, Stulak et al. (64) addressed the ethical
problem after the use of autograft in Ross’s operation.
The use of biological derivatives in fact poses some
ethical problems when the chances of procedure failure or
reintervention are not negligible. The problem of durability
of allogeneic and autologous tissues should be addressed
with the patient during the counselling process. On the
other hand, the benefit of low risk of infection relapse and
the impact on quality of life related to the avoidance of lifelong anticoagulant therapy should be discussed.
Take-home messages and an algorithm based
on evidence
The evidence discussed above indicates that modern LSE
surgery should involve the use of a different strategies
according to the location and extent of the infection.
Conventional stented xenograft and mechanical prosthetic
should be considered similar alternatives for localized LSE
or combined with patch reconstruction in case of more
abscess formation; mechanical valves should be preferred
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in cases of mitral valve endocarditis and biological valves
should be used in patients older than 55 years of age in
aortic position.
Due to its higher risk of structural valve deterioration,
lack of availability and difficult learning curve, the
use of homografts is limited to PVE or when complex
reconstruction of the mitro-aortic curtain or aortic root
is needed. The miniroot implant is probably the most
adaptable technique for complicated LSE and most
appropriate in case of demolitive surgery. Cryopreserved
mitro-aortic tissue allows the complete or partial
replacement of the mitral valve in case of aggressive lesions
involving the trigones, the aortic root or cardiac and
extracardiac fistulas. However, this type of surgical approach
requires adequate surgeon’s and center’s experience.
The use of the autograft can be considered in young
patients or in particular conditions such as women in
childbearing age or in case of contraindications to longterm anticoagulation. The use of PA should be limited to
centers that have proven experience with solid results and
only to cases where a conventional biological or mechanical
prosthesis is not indicated for clinical or technical reasons.
On the basis of the evidence examined in this study,
we propose an algorithm assisting the choice of the valve
substitute in different clinical conditions (Figures 4,5). In this
algorithm, technical, anatomical and imaging determinants
are considered, as well as the clinical characteristics of the
patient, the orientation of the guidelines and institutions
with the greatest experience in the treatment of LSE.
Due to the strong impact on post-operative mortality,
special relevance should be given to timing, which influences
the risk of neurological complications, and the extension of
the infection. Despite evidence suggests that early surgery
may improve survival in patients with complicated IE, an
increased risk of recurrence and postoperative valvular
dysfunctions has been reported (6,11,14,23,26,30).
The most important factors associated with long-term
outcomes are preoperative multiorgan failure, prosthetic
mechanical valve IE, vegetation size ≥15 mm, and timing of
surgical treatment. Importantly, up to one third of potential
candidates do not undergo surgery and these patients
experience extremely high mortality rates (37,74,75).
The lack of RCT in this field and the difficulty to design
this type of studies in the case of non-elective conditions
further complicates the possibility to achieve a univocal
consensus on the best strategy to be adopted in each form
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Figure 4 Take-Home Messages and Clinical Algorithm for the Management of Left Side Endocarditis. GMT, guide medical therapy; ACC/
AHA, American College of Cardiology/American Heart association; ESC, European Society of Cardiologists; IE, infective endocarditis;
LSE, left side endocarditis; TTE, transthoracic echocardiography.
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Figure 5 Take-home messages and clinical algorithm for the choice of optimal valve substitute for LSE. BP, bioprosthetic; MP, mechanical
prosthetic; PVE, prosthetic valve endocarditis; ACC/AHA, American College of Cardiology/American Heart association; ESC, European
Society of Cardiologists; IE, infective endocarditis; LSE, left side endocarditis; TTE, transthoracic echocardiography.

of LSE and further validation studies are needed.
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